Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis.
Animals
Antibody-Dependent Cell Cytotoxicity
Broadly Neutralizing Antibodies
/ biosynthesis
Complement Activation
Dependovirus
/ genetics
Genetic Therapy
Genetic Vectors
HIV
/ immunology
HIV Infections
/ immunology
Host-Pathogen Interactions
Humans
Immunization, Passive
Phagocytosis
Treatment Outcome
AAV
Fc receptor
HIV
VRC07
broadly neutralizing antibody
humanized mice
innate immunity
vectored immunoprophylaxis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
06
2021
accepted:
24
08
2021
entrez:
4
10
2021
pubmed:
5
10
2021
medline:
24
12
2021
Statut:
epublish
Résumé
HIV-1 broadly neutralizing antibodies (bNAbs) targeting the viral envelope have shown significant promise in both HIV prevention and viral clearance, including pivotal results against sensitive strains in the recent Antibody Mediated Prevention (AMP) trial. Studies of bNAb passive transfer in infected patients have demonstrated transient reduction of viral load at high concentrations that rebounds as bNAb is cleared from circulation. While neutralization is a crucial component of therapeutic efficacy, numerous studies have demonstrated that bNAbs can also mediate effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and antibody-dependent complement deposition (ADCD). These functions have been shown to contribute towards protection in several models of HIV acquisition and in viral clearance during chronic infection, however the role of target epitope in facilitating these functions, as well as the contribution of individual innate functions in protection and viral clearance remain areas of active investigation. Despite their potential, the transient nature of antibody passive transfer limits the widespread use of bNAbs. To overcome this, we and others have demonstrated vectored antibody delivery capable of yielding long-lasting expression of bNAbs
Identifiants
pubmed: 34603314
doi: 10.3389/fimmu.2021.734304
pmc: PMC8479175
doi:
Substances chimiques
Broadly Neutralizing Antibodies
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
734304Subventions
Organisme : NIDA NIH HHS
ID : DP2 DA040254
Pays : United States
Organisme : NIAID NIH HHS
ID : K22 AI102769
Pays : United States
Informations de copyright
Copyright © 2021 Phelps and Balazs.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Annu Rev Virol. 2014 Nov;1(1):427-51
pubmed: 26958729
Nat Med. 2009 Aug;15(8):901-6
pubmed: 19448633
J Clin Invest. 2019 Jan 2;129(1):182-191
pubmed: 30475230
Science. 1994 Nov 11;266(5187):1024-7
pubmed: 7973652
J Virol. 2017 Sep 27;91(20):
pubmed: 28768869
Science. 1965 Aug 13;149(3685):754-6
pubmed: 14325163
Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):833-8
pubmed: 25561553
Mol Ther. 2007 Jun;15(6):1153-9
pubmed: 17375065
Cell. 2014 Sep 11;158(6):1243-1253
pubmed: 25215485
J Virol. 2014 Nov;88(21):12895-906
pubmed: 25165110
Immunity. 2019 Mar 19;50(3):567-575.e5
pubmed: 30850342
Nat Microbiol. 2019 May;4(5):734-747
pubmed: 30886356
AIDS Res Hum Retroviruses. 2012 Nov;28(11):1444-57
pubmed: 23035746
Cancer Res. 2007 Sep 15;67(18):8882-90
pubmed: 17875730
PLoS Pathog. 2020 Feb 24;16(2):e1008083
pubmed: 32092122
Nature. 2011 Nov 30;481(7379):81-4
pubmed: 22139420
J Virol. 2015 Aug;89(16):8334-45
pubmed: 26041300
PLoS Pathog. 2021 Mar 15;17(3):e1009363
pubmed: 33720973
Stat Commun Infect Dis. 2019;11(1):
pubmed: 33312415
Lancet HIV. 2019 Dec;6(12):e809-e811
pubmed: 31439533
PLoS Med. 2017 Nov 14;14(11):e1002436
pubmed: 29136030
Retrovirology. 2018 Oct 16;15(1):70
pubmed: 30326938
J Virol. 1998 Nov;72(11):8568-77
pubmed: 9765395
Nat Rev Drug Discov. 2019 May;18(5):358-378
pubmed: 30710128
J Virol. 2011 May;85(10):4828-40
pubmed: 21389135
J Infect Dis. 2021 May 02;:
pubmed: 34009371
Stat Commun Infect Dis. 2017 Jan;9(1):
pubmed: 29218117
PLoS Pathog. 2019 Dec 16;15(12):e1008064
pubmed: 31841557
Sci Transl Med. 2017 Sep 6;9(406):
pubmed: 28878010
Mol Cancer Ther. 2008 Aug;7(8):2517-27
pubmed: 18723496
Immunol Rev. 2006 Dec;214:73-91
pubmed: 17100877
Nat Rev Immunol. 2008 Jan;8(1):34-47
pubmed: 18064051
J Virol. 2017 Jul 27;91(16):
pubmed: 28592534
Immunol Rev. 2017 Jan;275(1):262-270
pubmed: 28133810
J Virol. 2016 Jun 10;90(13):6127-6139
pubmed: 27122574
Cell Host Microbe. 2019 Jun 12;25(6):873-883.e5
pubmed: 31194940
Nat Commun. 2017 Jun 08;8:15711
pubmed: 28593989
Immunity. 2013 Jan 24;38(1):176-86
pubmed: 23313589
Immunol Rev. 2017 Jan;275(1):145-160
pubmed: 28133802
Front Cell Infect Microbiol. 2020 Apr 23;10:176
pubmed: 32391289
Nat Immunol. 2019 Mar;20(3):374
pubmed: 30705417
Mol Ther. 2008 Jul;16(7):1189-99
pubmed: 18500252
Nat Rev Genet. 2020 Apr;21(4):255-272
pubmed: 32042148
Nat Commun. 2016 Mar 03;7:10844
pubmed: 26936020
Lancet HIV. 2019 Apr;6(4):e230-e239
pubmed: 30885692
Proc Natl Acad Sci U S A. 2020 Aug 4;117(31):18754-18763
pubmed: 32690707
Nature. 2013 Nov 14;503(7475):224-8
pubmed: 24172905
J Virol. 2014 Nov;88(21):12669-82
pubmed: 25142607
J Virol. 2002 Sep;76(17):8769-75
pubmed: 12163597
Sci Transl Med. 2021 Mar 17;13(585):
pubmed: 33731434
Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10220-5
pubmed: 20479244
J Virol. 1994 Jun;68(6):4031-4
pubmed: 7514684
PLoS Pathog. 2015 Aug 06;11(8):e1005090
pubmed: 26248318
Annu Rev Immunol. 2016 May 20;34:635-59
pubmed: 27168247
EMBO J. 1991 Dec;10(12):3941-50
pubmed: 1657596
N Engl J Med. 2012 Apr 5;366(14):1275-86
pubmed: 22475592
J Gen Virol. 2002 May;83(Pt 5):973-978
pubmed: 11961250
Front Immunol. 2015 Jun 02;6:262
pubmed: 26082779
Biotechnol Bioeng. 2004 Sep 5;87(5):614-22
pubmed: 15352059
Nat Commun. 2011 Dec 20;2:599
pubmed: 22186895
Hum Gene Ther Methods. 2016 Feb;27(1):1-12
pubmed: 26757051
Sci Transl Med. 2014 Jul 2;6(243):243ra88
pubmed: 24990883
Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4005-10
pubmed: 16537476
PLoS Pathog. 2018 Dec 5;14(12):e1007395
pubmed: 30517201
AIDS. 2016 Jun 19;30(10):1543-51
pubmed: 27243773
Cell Res. 2010 Jan;20(1):34-50
pubmed: 20010915
Trends Immunol. 2015 Jun;36(6):325-36
pubmed: 25981969
Sci Transl Med. 2014 Mar 19;6(228):228ra39
pubmed: 24648342
Virology. 1999 Aug 15;261(1):8-14
pubmed: 10484751
PLoS One. 2014 May 12;9(5):e97229
pubmed: 24820481
Blood. 2012 Jun 14;119(24):5640-9
pubmed: 22535666
J Virol. 2002 Aug;76(15):7554-9
pubmed: 12097568
Nat Rev Drug Discov. 2021 Mar;20(3):173-174
pubmed: 33495615
MAbs. 2016 Nov/Dec;8(8):1512-1524
pubmed: 27492264
Science. 2016 May 20;352(6288):1001-4
pubmed: 27199430
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):18002-18009
pubmed: 32665438
Nat Biotechnol. 2005 May;23(5):584-90
pubmed: 15834403
Science. 2019 Nov 29;366(6469):1139-1143
pubmed: 31780559
J Virol. 2015 Jun;89(11):5895-903
pubmed: 25787288
J Struct Biol. 2016 Apr;194(1):78-89
pubmed: 26850169
J Biol Chem. 2001 Mar 2;276(9):6591-604
pubmed: 11096108
Nature. 2007 Sep 6;449(7158):101-4
pubmed: 17805298
mBio. 2019 Jul 2;10(4):
pubmed: 31266872
J Leukoc Biol. 2019 Jun;105(6):1319-1329
pubmed: 31107565
Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18921-5
pubmed: 23100539
Nature. 2014 Oct 30;514(7524):642-5
pubmed: 25119033
J Virol. 1988 Aug;62(8):2745-54
pubmed: 2839699
Antibodies (Basel). 2020 Nov 17;9(4):
pubmed: 33212886
AIDS Res Hum Retroviruses. 1994 Dec;10(12):1651-8
pubmed: 7888224
AIDS. 2014 Jan 14;28(2):163-9
pubmed: 24361678
Proc Natl Acad Sci U S A. 1990 Mar;87(6):2211-5
pubmed: 2156265
AIDS. 2014 Nov 13;28(17):2523-30
pubmed: 25160934
PLoS Pathog. 2016 Jan 08;12(1):e1005315
pubmed: 26745376
Nat Med. 2014 Mar;20(3):296-300
pubmed: 24509526
Science. 2013 Sep 13;341(6151):1199-204
pubmed: 24031012
Innate Immun. 2018 Nov;24(8):452-465
pubmed: 30236030
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11181-6
pubmed: 21690411
J Virol. 2015 Jun;89(11):5752-5
pubmed: 25762739
J Virol. 2006 Nov;80(22):11040-54
pubmed: 16956943
J Exp Med. 2014 Sep 22;211(10):2061-74
pubmed: 25155019
N Engl J Med. 2021 Mar 18;384(11):1003-1014
pubmed: 33730454
Nature. 2016 May 5;533(7601):105-109
pubmed: 27120156
Structure. 2015 Sep 1;23(9):1573-1583
pubmed: 26211613
J Virol. 2012 Nov;86(21):11521-32
pubmed: 22896626
Front Immunol. 2020 Jul 30;11:1635
pubmed: 32849559
Nat Rev Immunol. 2018 Jan;18(1):46-61
pubmed: 29063907
Nature. 2011 Sep 22;477(7365):466-70
pubmed: 21849977
J Virol. 2006 Feb;80(4):1874-85
pubmed: 16439543
Mol Ther Methods Clin Dev. 2019 Jun 12;14:100-112
pubmed: 31334303
J Virol. 1981 Oct;40(1):241-7
pubmed: 6270377
PLoS One. 2017 Dec 15;12(12):e0188830
pubmed: 29244806
EMBO J. 2001 Jun 15;20(12):3282-91
pubmed: 11406604
Nat Med. 2009 Aug;15(8):951-4
pubmed: 19525965
Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10134-7
pubmed: 1719545